JPRN-jRCT1080220060未知4 期
Post-marketing clinical study on milnacipran hydrochloride
ASAHIKASEI PHARMA CORPORATIO0 个研究点开始时间: 2005年9月8日最近更新:
试验速览
- 阶段
- 4 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •1)male or female patients aged 20 to 64 years;
- •2)patients who have been diagnosed with DSM-4 depressive disorders , etc.
- •Exclusion criteria
- •1)patients with ischuria (such as prostatic disorders);
- •2)patients with glaucoma, etc.
排除标准
- 未提供
研究者
相似试验
未知
4 期
A postmarketing clinical study of milnacipran hydrochloride (MIL001) for the treatment of depressioMajor depressionJPRN-jRCT1080220706ASAHI KASEI PHARMA CORPORATIO705
已完成
不适用
A study of the efficacy of milnacipran in patients with major depressive disorder (MDD) after SSRI treatment failure, and biological research for MDD using peripheral blood.Major depressive disorderJPRN-UMIN000003516Department of Psychiatry, Chiba University Graduate School of Medicine, Division of Psychiatry, Chiba University Hospital40
已完成
3 期
Study of Milnacipran for the Treatment of FibromyalgiaFibromyalgiaNCT00314249Forest Laboratories1,025
已完成
4 期
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of FibromyalgiaFibromyalgiaNCT01014585Forest Laboratories340
已完成
4 期
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of FibromyalgiaFibromyalgiaNCT01077375Forest Laboratories107